MEI Pharma reports $26.9M cash, no debt; continues strategic alternatives review

Lite Strategy, Inc.

Cash, cash equivalents and short-term investments at Sept 30, 2024: $26.9M; no outstanding debt.
Strategic alternatives review ongoing; Oppenheimer & Co. acting as exclusive financial advisor.
Reduction-in-force initiated as part of cash preservation efforts; further stages planned.
No assurance that any transaction will result; updates only if Board determines disclosure appropriate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.